CA3227802A1 - Methods and compositions for treatment of kras mutant cancer - Google Patents

Methods and compositions for treatment of kras mutant cancer

Info

Publication number
CA3227802A1
CA3227802A1 CA3227802A CA3227802A CA3227802A1 CA 3227802 A1 CA3227802 A1 CA 3227802A1 CA 3227802 A CA3227802 A CA 3227802A CA 3227802 A CA3227802 A CA 3227802A CA 3227802 A1 CA3227802 A1 CA 3227802A1
Authority
CA
Canada
Prior art keywords
poziotinib
inhibitor
kras
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3227802A
Other languages
English (en)
French (fr)
Inventor
John V. Heymach
Jacqulyne P. ROBICHAUX
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3227802A1 publication Critical patent/CA3227802A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3227802A 2021-07-29 2022-07-29 Methods and compositions for treatment of kras mutant cancer Pending CA3227802A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227237P 2021-07-29 2021-07-29
US63/227,237 2021-07-29
PCT/US2022/074317 WO2023010121A1 (en) 2021-07-29 2022-07-29 Methods and compositions for treatment of kras mutant cancer

Publications (1)

Publication Number Publication Date
CA3227802A1 true CA3227802A1 (en) 2023-02-02

Family

ID=85087345

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3227802A Pending CA3227802A1 (en) 2021-07-29 2022-07-29 Methods and compositions for treatment of kras mutant cancer

Country Status (7)

Country Link
US (1) US20240374597A1 (https=)
EP (1) EP4376959A4 (https=)
JP (1) JP2024527109A (https=)
KR (1) KR20240051145A (https=)
CN (1) CN118043075A (https=)
CA (1) CA3227802A1 (https=)
WO (1) WO2023010121A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
CN121846289A (zh) * 2024-10-12 2026-04-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 包括nampt抑制剂和kras抑制剂的组合物及其用途
CN119607214B (zh) * 2025-02-17 2025-06-20 四川大学华西医院 Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190749A1 (ru) * 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
BR112021016149A2 (pt) * 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230028798A (ko) * 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
KR102379786B1 (ko) * 2020-08-13 2022-03-25 정부환 레일 형식 보행보조기구 방향전환장치

Also Published As

Publication number Publication date
JP2024527109A (ja) 2024-07-19
US20240374597A1 (en) 2024-11-14
EP4376959A4 (en) 2025-06-11
CN118043075A (zh) 2024-05-14
EP4376959A1 (en) 2024-06-05
WO2023010121A1 (en) 2023-02-02
KR20240051145A (ko) 2024-04-19

Similar Documents

Publication Publication Date Title
US20240374597A1 (en) Methods and compositions for treatment of kras mutant cancer
JP6689400B2 (ja) チェックポイント阻害剤と組み合わされた腫瘍溶解性ウイルスによるがん療法
CN107073099B (zh) 用于治疗癌症的联合方法
JP2020525427A (ja) 癌を処置するための方法
US20250281527A1 (en) Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress
WO2022061112A1 (en) Combination treatment for cancer
US20210386780A1 (en) Methods for treating cancer with double stranded rna sensor activators and adoptive cell therapy
US20210260051A1 (en) Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
US20230406949A1 (en) Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment
US20220175744A1 (en) Combinations of transcription inhibitors and immune checkpoint inhibitors for treatment of disease
US20240100021A1 (en) Combination Therapy Schedules to Treat Cancer
US12465610B2 (en) Compounds and methods for the treatment of PKR-associated diseases
WO2022155311A1 (en) Methods and systems for analysis of drug target engagement and treatment of cancer
US20230255978A1 (en) Methods for treating glioblastoma
ES2763118T3 (es) Terapia contra el cáncer con parvovirus H-1 combinado con un anticuerpo anti-PD1 o anticuerpo anti Pd-L-1
WO2026041647A1 (en) Small molecule targeting tlr4 overexpressing tumors and associated immunosuppressive, angiogenic and fibrotic complications
CA3210156A1 (en) Methods of treating cancer with poziotinib
HK1261030B (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
HK1261030A1 (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
NZ745264B2 (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250725

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250725